Answers are grounded in this paper and cite their sources.
Aims: The beneficial effect of intra-hippocampal single dose of Aminoguanidine (AG) on deficit in experimental animal model of diabetes has been reported. This study was conducted to investigate the effects of seven day intra-hippocampal AG injections on memory impairment induced by DM and its role in the apoptosis. Materials and Methodology: 72 male rats were divided into 9 groups: control (C), control treated with normal saline (CS), control treated with AG 10, 30 and 90 µg/rat, diabetics (D) and diabetics treated with AG 10, 30 and 90 µg/rat. Then the passive avoidance learning (PAL) and the Bcl-2 family genes was measured by RT-PCR. Results: AG significantly ameliorated the cognitive deficits (the number of trials to acquisition TA, step-through latency of retention STLr and the time spent in the dark compartment TDC) in diabetic rats. Moreover, AG treatment significantly modified the diabetes induced changes in Bax, Bcl–2 and Bcl-xl expression. Conclusions: Seven day intra-hippocampal injections of AG, may improve the impaired cognitive tasks in diabetic rats by increasing either Bcl-2 or Bcl-xl and decreasing Bax ratios.
No takes yet. Share an insight, caveat, or question.
Mohammad Reza Jafari (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: